Urinary bladder disorder

This Phase 3 trial tests whether the immunotherapy drug pembrolizumab (Keytruda) can help prevent bladder cancer from returning after surgery. About 739 patients with muscle-invasive or locally advanced urothelial cancer are randomly assigned to receive pembrolizumab or just be o…

This early-stage trial tests a treatment called CG0070, a virus-based therapy given directly into the bladder, after standard surgery for intermediate-risk non-muscle invasive bladder cancer. About 20 participants will receive the treatment to see if it is safe and helps prevent …

This study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …

This Phase III trial tests whether adding the immunotherapy drug atezolizumab to standard chemoradiotherapy helps people with muscle-invasive bladder cancer that hasn't spread. About 475 participants receive either chemoradiotherapy alone or with atezolizumab. The main goal is to…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…

This phase 3 trial tests whether adding two immunotherapy drugs—pembrolizumab and enfortumab vedotin—before and after bladder removal surgery helps people with muscle-invasive bladder cancer live longer without the cancer coming back. The study includes patients who cannot take o…

This study tests a robotic-assisted surgery tool to remove bladder lesions. About 30 adults with small bladder tumors will undergo the procedure. The goal is to see if the robot helps remove the tumor in one piece with healthy tissue around it, which may improve diagnosis and red…

This phase 3 trial is testing a drug called ONCOFID-P-B for people with a type of bladder cancer that hasn't responded to standard BCG therapy. The drug is given directly into the bladder weekly for 12 weeks, then monthly for a year if it works. The goal is to see if it can contr…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…

This early-phase trial tests whether a robotic bladder transplant from a deceased donor is feasible and safe for people with severe bladder problems. Only 5 participants will be enrolled. The main goal is to see if the transplanted bladder gets good blood flow. If it works, it mi…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This phase II trial tests whether adding the immunotherapy drug durvalumab after surgery, chemotherapy, and radiation can help prevent bladder cancer from coming back in people with muscle-invasive bladder cancer. About 82 participants will receive either durvalumab or a placebo …

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This study tests a liquid medicine called mirabegron in children aged 6 months to 3 years who have bladder problems due to nerve damage (neurogenic detrusor overactivity). The goal is to see if the medicine helps the bladder hold more urine safely, reducing leaks and pressure. Ch…

This trial investigates whether combining two drugs—BCG and gemcitabine—can safely and effectively treat a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC) that has come back after previous BCG treatment. Participants receive BCG directly into the bladder …

This study follows 100 men who have had prostate surgery and still struggle with stress urinary incontinence (leaking urine when coughing or moving). They receive an adjustable implant called REMEEX to help control leakage. Researchers will track how well it works, side effects, …

This study is testing a new, recharge-free nerve stimulator (Axonics SNM system) in 144 adults with overactive bladder or fecal incontinence. The device is implanted to stimulate sacral nerves and improve control. Researchers will measure quality of life and symptom changes over …

This study tests a combination of two drugs—tazemetostat and pembrolizumab—in people with advanced bladder cancer that has spread. The goal is to find the best dose and see if the combo works better than pembrolizumab alone. About 30 adults with locally advanced or metastatic uro…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from growing after initial chemotherapy. About 654 patients will receive either the combination or avelumab alone as maintenance therapy. The goal is to s…

This study tests a drug called olaparib in 60 people with advanced bladder or related cancers that have specific DNA repair defects. Olaparib blocks a protein that cancer cells need to fix their DNA, which may stop the cancer from growing. The goal is to see if the drug can shrin…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This phase 3 trial tests a new approach for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive either a combination of TAR-200 (a drug placed directly into the bladder) plus cetrelimab (an immunotherapy), or sta…

This study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either receive TAR-200 or standard chemotherapy placed directly into the bladder. The goal is to see if TAR-200 can keep th…

This study follows about 200 women who had surgery with the GYNECARE TVT EXACT sling to treat stress urinary incontinence (leaking urine when coughing or sneezing). Researchers check if the sling still works 5 to 10 years later by using a cough test and patient questionnaires. Th…

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…

This phase 3 trial tests two new approaches for high-risk bladder cancer that hasn't spread into the muscle. One group gets a drug called TAR-200 placed directly into the bladder plus an immunotherapy drug (cetrelimab). Another group gets TAR-200 alone. These are compared to the …

This phase 3 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with a targeted therapy (enfortumab vedotin) works better than current standard care for people with muscle-invasive bladder cancer who cannot take or refuse cisplatin chemotherapy. A…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This early-stage study tests a new treatment called TAR-210 in 5 Japanese patients with a type of bladder cancer that has specific genetic changes (FGFR mutations). The treatment is placed directly into the bladder to deliver the drug erdafitinib. The main goal is to see if it is…

This early-phase study tests a personalized cell therapy for people with certain cancers (bladder, melanoma, head/neck, ovarian, lung, esophageal, stomach, or sarcoma) whose tumors have a specific marker called MAGE-A4. The treatment involves taking a patient's own immune cells, …

This study follows 60 men with an enlarged prostate who already used the Butterfly device for a year. Researchers will track safety and symptom relief for up to 5 years. The goal is to see if the device remains effective and safe over the long term.

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This large Phase 3 trial is testing whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy can help people with advanced bladder cancer that cannot be removed by surgery. Over 1,200 participants worldwide are receiving either che…

This phase 3 trial is testing whether adding the immunotherapy drug durvalumab to standard BCG treatment can safely control high-risk non-muscle-invasive bladder cancer. About 100 adults who have never received BCG before will get both treatments for up to a year. The main goal i…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This study tests an experimental drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced urothelial cancer that has spread. The goal is to see if it works better than standard chemotherapy. About 375 participants will be enrolled, some who have not…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can improve outcomes for people with stage III bladder cancer that has spread to nearby lymph nodes. The goal is to see if the combination helps shrink tumors and allows patie…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study aimed to see if adding ANKTIVA to standard BCG treatment works better than BCG alone for people with a high-grade type of bladder cancer that hasn't spread into the muscle. It was designed for adults with papillary tumors who had not received BCG before or had limited …

This phase II trial is testing whether adding the immunotherapy drug pembrolizumab to the chemotherapy drug gemcitabine can help patients with a type of bladder cancer that does not respond to the usual BCG treatment. The study involves 161 participants and looks at how many pati…

This early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…

This phase 2 trial tests a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific genetic change (TSC1 or TSC2 mutation). The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if the drug can shrink tumors and h…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This Phase 2 trial is testing whether combining two drugs, durvalumab (an immunotherapy) and olaparib (a targeted therapy), can help people with advanced bladder cancer who are not healthy enough for standard platinum chemotherapy. About 154 participants will receive either the d…

This study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot …

This study tests a drug called UGN-102 for people with a low-grade type of bladder cancer that hasn't spread into the muscle. The drug is given directly into the bladder to destroy tumors without surgery. The main goal is to see if the cancer disappears completely after 3 months.…

This early-phase study tests a combination of three drugs (tremelimumab, durvalumab, and belinostat) in people with advanced bladder cancer that has spread or cannot be removed surgically. The main goal is to find the safest dose and understand side effects. About 9 adults who ha…

This phase III trial tests whether an immune-enhancing nutritional supplement, taken before and after bladder cancer removal surgery, can reduce post-operative complications and infections. About 203 participants are randomly assigned to receive either the supplement or a placebo…

This study tests whether adding the immunotherapy drug pembrolizumab to standard BCG treatment helps people with high-risk non-muscle invasive bladder cancer stay cancer-free longer. About 1,400 participants will receive either BCG alone or BCG plus pembrolizumab. The goal is to …

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemoradiotherapy can help people with muscle-invasive bladder cancer live longer without their cancer returning or spreading. About 520 participants who are eligible for non-surgical treatment will …

This study compares two surgical procedures for stress urinary incontinence (leaking urine when coughing, sneezing, or lifting). One uses a mesh tape (transvaginal tape), the other tightens the urethral ligaments without mesh. Researchers will follow 200 women for one year to see…

This study looked at 70 men with an enlarged prostate and overactive bladder symptoms. Some received a Botox injection into the prostate during surgery, while others took standard medication after surgery. The Botox group showed better symptom scores at 12 weeks, suggesting a pot…

This study tests a pill called erdafitinib in 20 people whose non-muscle invasive bladder cancer has returned after standard treatments like BCG. All participants have a specific change in the FGFR3 gene, which the drug targets. They take the pill for about a month before their s…

This early-phase trial tests whether adding the blood pressure drug propranolol to standard immunotherapy and chemotherapy can help shrink bladder cancer that has spread to lymph nodes before surgery. The study enrolls 12 patients and primarily checks for safety and side effects.…

This study tested whether two immunotherapy drugs (durvalumab and tremelimumab) work better than standard chemotherapy for people with advanced bladder cancer that has spread (stage IV). Over 1,100 participants received either the drug combination, durvalumab alone, or chemo. The…

This study tests whether adding immunotherapy drugs (nivolumab, with or without BMS-986205) to standard chemotherapy before and after bladder cancer surgery helps more people achieve a complete response and live longer without the cancer returning. About 855 adults with muscle-in…

This study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will receive either the combination or BCG alon…

This early-phase trial tests a combination of three drugs—bortezomib, gemcitabine, and doxorubicin—in people with advanced urothelial cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the highest safe dose of the two chemotherapy drugs when …

This program gives patients with high-risk non-muscle invasive bladder cancer access to TAR-200 before it is officially approved. TAR-200 is a device placed into the bladder that releases medication over time. It is for patients who have tried all other treatments and cannot join…

This phase II trial tests a combination of two chemotherapy drugs, gemcitabine and cisplatin, in people with muscle-invasive bladder cancer whose tumors have specific DNA repair gene changes (DDR alterations). The goal is to see if these patients can avoid bladder removal surgery…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…

This phase 2 trial is testing whether the immunotherapy drug Keytruda (pembrolizumab) can help people with muscle-invasive bladder cancer avoid having their bladder removed. About 46 participants will receive two cycles of Keytruda, then doctors will check if the cancer has compl…

This study tests a device called SUI-100 for women aged 22-70 with mild-to-moderate stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). About 130 participants will be randomly assigned to receive either the real device or a sham (fake) treatment. T…

This early-phase trial tests a new drug called AI-061, which combines two immune-boosting antibodies (anti-PD-1 and anti-CTLA-4) into one treatment. The study will enroll 18 adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe…

This study tests two immunotherapy drugs (nivolumab with or without urelumab) given before bladder removal surgery in 15 patients with muscle-invasive bladder cancer who cannot or refuse standard chemotherapy. The goal is to see if adding urelumab boosts the immune response again…

This study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. …

This study compares two types of sling surgery for stress urinary incontinence (leaking urine with cough or sneeze) in women who are also having surgery for pelvic organ prolapse. One sling uses a single incision, the other uses two incisions. The trial will enroll 180 women and …

This study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…

This early study tests a new artificial urinary sphincter device in 6 men with stress incontinence. The device is implanted to help control urine leakage. Researchers will check how many devices are successfully activated and how many need to be removed or revised within 6 months…

This study tests whether adding an immune-boosting drug called N-803 to the standard BCG treatment works better than BCG alone for people with a high-risk type of bladder cancer that hasn't invaded the muscle. About 369 participants will receive either the combination or BCG alon…

This study tests a targeted cancer drug called erdafitinib, alone or combined with an immunotherapy (cetrelimab) and/or chemotherapy, in 125 people with advanced urothelial cancer that has spread. The goal is to find safe doses and see if the treatments shrink tumors. Participant…

This study tests a new artificial urinary sphincter device in 6 women with stress incontinence (leaking urine during activity). The goal is to see if the device is safe and works well. Researchers will check how many devices need to be removed or fixed, and if pad weight tests sh…

This study tests whether the immunotherapy drug atezolizumab can delay or prevent bladder cancer from coming back after surgery. It includes 761 high-risk patients whose blood tests showed cancer DNA after bladder removal. Participants receive either atezolizumab or a placebo to …

This phase III trial is testing whether a different strain of BCG (Tokyo-172) works better than the standard TICE strain for high-grade bladder cancer that hasn't spread into muscle. It also looks at whether giving a BCG vaccine under the skin before the usual bladder treatment h…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder surgery to prevent acute kidney injury. The surgery can reduce blood flow to the kidneys, and these drugs may help protect them. 90 adults with normal or mildly reduced kidney func…

This early-phase study tested a new drug called UGN-201 in 10 people with bladder cancer who were scheduled to have their bladder removed. The main goal was to check the drug's safety and see if it caused any serious side effects or surgery delays. Researchers also looked for sig…

This was a planned Phase 3 study testing NDV-01, a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder, for people with a type of bladder cancer that did not respond to BCG therapy. The trial was withdrawn before enrolling any partici…

This was a planned Phase 3 study comparing a new drug, NDV-01 (a combination of two chemotherapy drugs), against simple observation in people with intermediate-risk non-muscle invasive bladder cancer. The goal was to see if the drug could prevent the cancer from coming back after…

This study tests whether using a lung ultrasound during robotic prostate or bladder surgery can help doctors set the breathing machine to the right pressure, reducing lung collapse and other breathing problems. 88 adults with mild or no lung disease are enrolled. The approach is …

This was a small early-stage trial testing a mix of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for people with advanced bladder cancer who had not yet received any treatment. The goal was to see if the combination was safe and could slow cancer growth. However, th…

This pilot study is testing whether a less frequent dosing schedule of the drug enfortumab vedotin (EV), given alone or with pembrolizumab, can still control advanced bladder cancer. About 60 adults with locally advanced or metastatic urothelial carcinoma will receive EV on a mod…

This phase 2 trial is testing a combination of three drugs—sacituzumab govitecan, zimberelimab, and domvanalimab—given before and after surgery for muscle-invasive bladder cancer. The study includes 70 patients who cannot take standard cisplatin chemotherapy. The main goal is to …

This phase 3 trial is testing a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not improve after standard BCG therapy. The treatment uses a modified virus to target and destroy cancer cells. About 190 pa…

This study tests a new treatment called AMDC-USR (iltamiocel) for women who still have stress urinary incontinence after having surgery for it. The treatment uses the patient's own muscle cells injected into the urinary sphincter to strengthen it. Half of the 96 participants get …

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before and after bladder removal surgery helps people with muscle-invasive bladder cancer. About 1,063 participants will receive either the drug combo or standard care. The goal is to see i…

This early-phase study tests a combination of two drugs—romidepsin and durvalumab—given directly into the bladder for people with muscle-invasive bladder cancer who cannot receive standard chemotherapy. The goal is to see if the combination is safe and can shrink or eliminate tum…

This study tests a new type of daily radiation therapy for muscle-invasive bladder cancer that adapts to changes in the body each day. The goal is to see if this approach lowers the chance of diarrhea and other bowel problems compared to standard radiation. About 110 adults with …

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This study looked at whether adding the drug cidofovir to usual care helps people who develop painful bladder bleeding from the BK virus after a stem cell transplant. About 27 participants received either cidofovir or standard supportive care. The goal was to see if symptoms impr…

This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…

This phase 2 trial is testing a drug called ado-trastuzumab emtansine (Kadcyla) in 131 adults with advanced solid tumors that have a specific HER2 gene change. The drug combines an antibody that targets HER2 with a chemotherapy agent, aiming to deliver treatment directly to cance…

This study tests a small implant called INTIBIA that stimulates a nerve in the leg to help control sudden, strong urges to urinate. About 208 adults with overactive bladder and frequent leaking episodes will receive the implant. The goal is to see if it safely reduces leaking by …

This early-stage study is testing a combination of three drugs—sacituzumab tirumotecan, enfortumab vedotin, and pembrolizumab—in people with advanced bladder cancer that has spread or cannot be surgically removed. The trial has two parts: first, to find safe doses of the two-drug…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy helps people with bladder cancer that has spread to nearby lymph nodes. About 60 participants will receive either chemo alone or chemo plus durvalumab, followed by maintenance durvalumab fo…

This phase 2 trial is testing whether adding propranolol, a common blood pressure drug, to standard immunotherapy can help control advanced bladder cancer. The study enrolled 6 adults with urothelial carcinoma that has spread or cannot be removed by surgery. Researchers are prima…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This study tests whether giving immunotherapy drugs (nivolumab alone or with ipilimumab) before bladder cancer surgery is safe and does not delay the operation. The goal is to shrink the tumor, making surgery more effective. It involves 52 adults with muscle-invasive bladder canc…

This study planned to see if adding the daily pill vibegron to standard Botox bladder injections helps women with overactive bladder that hasn't improved with other treatments. Researchers aimed to compare changes in urgent leaks and symptom distress over 12 weeks. However, the t…

This study compares two surgical treatments for stress urinary incontinence in women: laparoscopic Burch colposuspension and transobturator tape. Sixty adult women who have not improved with non-surgical treatments will be randomly assigned to one surgery. Researchers will check …

This study looks at whether eating a diet rich in cruciferous vegetables (like broccoli, cauliflower, and cabbage) can help prevent bladder cancer from coming back in people with intermediate to very high-risk non-muscle invasive bladder cancer. About 250 participants will either…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This early-phase study tests whether a one-time injection of Botox into the bladder muscle can reduce urine leakage in women with stress urinary incontinence. Twenty women who have not improved with other treatments will receive the injection and be monitored for changes in leaka…

This phase 2 trial tests whether giving a live BCG vaccine directly into the bladder, followed by immunotherapy (atezolizumab) and standard chemotherapy (cisplatin/gemcitabine), can completely clear muscle-invasive bladder cancer before patients undergo bladder removal surgery. T…

This phase 3 trial tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment helps control high-risk non-muscle invasive bladder cancer better than BCG alone. Over 1,000 participants are enrolled, with some receiving the combination and others BCG only. The…

This study tests a new drug, UGN-103, given directly into the bladder for people with a low-grade, non-invasive bladder cancer that has a medium risk of coming back. The main goal is to see if the drug can make tumors disappear completely after 3 months. Researchers will also tra…

This study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) can prevent high-risk bladder cancer from coming back after surgery. About 230 adults with muscle-invasive bladder cancer will receive either the vaccine plus immunother…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This pilot study is testing a new device called UroRelief for stress urinary incontinence—leaking urine during exercise, coughing, or sneezing. The device is placed inside the urethra through a routine scope procedure. The study will check safety and whether it reduces leakage in…

This study tests a combination of two drugs, pemetrexed and avelumab, in people with a specific type of advanced bladder cancer that lacks a protein called MTAP. The goal is to see if this treatment can shrink or control the cancer. About 18 participants who have already tried ch…

This early-stage trial tests the safety of combining the immunotherapy drug pembrolizumab with radiation therapy for people with advanced bladder cancer. About 34 patients with either locally advanced or metastatic disease will receive pembrolizumab before and during radiation, t…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (gemcitabine and cisplatin) is safe and works better for people with advanced bladder cancer. About 54 participants will receive the combination treatment. The goal is to see if the combo…

This study tests whether the immunotherapy drug nivolumab, given after standard chemo-radiation, can help prevent bladder cancer from coming back. About 200 adults with localized muscle-invasive bladder cancer who cannot have bladder removal surgery are taking part. The main goal…

This study is for people with muscle-invasive bladder cancer that has gotten worse after earlier treatments. It tests several different drug combinations, chosen based on the specific genetic markers of each person's tumor. The main goal is to see if these combinations are safe a…

This study tests a new, simpler laparoscopic surgery for women with pelvic organ prolapse (when pelvic organs drop from their normal position). The goal is to restore anatomy and improve quality of life while reducing risks from surgical mesh. The study involves 60 women aged 30-…

This Phase 2 trial tests whether adding visugromab to the immunotherapy nivolumab helps shrink muscle-invasive bladder cancer before surgery. The study includes 31 patients who cannot take or refuse standard cisplatin chemotherapy. The main goal is to see how many patients have n…

This study was testing a new drug called VMB-100, which is an mRNA that tells muscle cells to produce a protein (IGF-1) to help repair the urethra sphincter. The goal was to improve muscle function and reduce urine leakage in women with moderate stress urinary incontinence. The s…

This early-stage trial tests a new way to treat high-grade bladder cancer that hasn't spread into the muscle. Doctors take immune cells from the patient's own tumor, grow them in a lab, and put them back into the bladder. The goal is to see if this is safe and can shrink or elimi…

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused …

This phase 2 trial is testing whether a combination of chemotherapy, an immunotherapy drug called toripalimab, and radiation can effectively treat muscle-invasive bladder cancer while allowing patients to keep their bladder. About 71 adults with this type of bladder cancer will r…

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This study looks at how well a new robotic surgery system (Medtronic Hugo) works for urologic procedures like removing prostate, bladder, or kidney tumors. About 144 adults will have surgery with the robot, and doctors will check if the surgery is completed without switching to a…

This phase 2 trial is testing whether the immunotherapy drug atezolizumab can help control muscle-invasive bladder cancer in patients who cannot undergo bladder removal surgery. About 79 participants will receive atezolizumab after standard chemo-radiotherapy. The main goal is to…

This study tests a drug called abemaciclib in 20 people with bladder cancer who cannot receive standard chemotherapy. Participants take the drug before their scheduled surgery to remove the bladder. Researchers will compare tumor samples taken before and after treatment to see ho…

This study tested a combination of two chemotherapy drugs, gemcitabine and docetaxel, placed directly into the bladder for people with early-stage bladder cancer who had not received standard BCG therapy. The goal was to see if this treatment could prevent the cancer from coming …

This study tests a new drug called BT8009, alone or with another drug (pembrolizumab), in people with advanced solid tumors like bladder, breast, lung, or ovarian cancer. The drug targets a protein called Nectin-4 found on some cancer cells. The trial aims to find safe doses and …

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This study tests whether combining two immune-boosting drugs, pembrolizumab and BCG, can keep high-risk bladder cancer from coming back. About 45 people with early-stage but aggressive bladder cancer will receive this combination as their first treatment. The goal is to see if mo…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…

This phase II trial tests a combination of an immunotherapy drug called sasanlimab and focused radiation given before bladder removal surgery in 33 patients with muscle-invasive bladder cancer who cannot take standard chemotherapy. The goal is to see if this approach is safe, fea…

This trial was designed to test two drugs—erdafitinib and atezolizumab—for people with muscle invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. Erdafitinib targets a specific gene change that can drive cancer growth, while atezolizumab helps the im…

This study tests a new treatment for people with a type of bladder cancer that has not improved with standard therapy. The treatment combines a standard immunotherapy (BCG) with an experimental drug (N-803), both given directly into the bladder through a catheter. The goal is to …

This study tests whether a precise type of radiation called SBRT can restore the effectiveness of immunotherapy drugs in people whose metastatic cancer has started to progress. About 69 adults with melanoma, lung, bladder, kidney, or head/neck cancers will receive radiation to up…

This phase II trial tests whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy and radiation can help people with muscle-invasive bladder cancer avoid bladder removal. The study enrolls 60 patients who cannot or choose not to have surgery. The m…

This phase 2 trial tested a combination of four chemotherapy drugs (5-FU, leucovorin, gemcitabine, and cisplatin) in 46 people with advanced or inoperable adenocarcinoma of the bladder, urethra, or urachus. The goal was to see how many patients' tumors shrank or disappeared. Rese…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study looks at whether measuring bladder wall thickness with an ultrasound can help predict treatment response in children aged 5-17 with lower urinary tract problems or bedwetting. Researchers will compare bladder wall measurements between the two groups and see if thicknes…

This study compares two imaging techniques—CT urography (CTU) and intravenous urography (IVU)—in 133 bladder cancer patients to see if CTU alone can effectively monitor the disease. Researchers want to determine if CTU provides clear enough images of the urinary tract to replace …

This study is testing a urine test called BladMetrix to see if it can detect bladder cancer returning after surgery. 500 adults with non-muscle invasive bladder cancer will provide urine samples during routine follow-up visits over 2 years. The test's accuracy will be compared to…

This early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…

This study is testing a new urine test that looks for specific markers of bladder cancer. The goal is to see if this simple, non-invasive test can accurately detect bladder cancer in 450 people who have blood in their urine, potentially reducing the need for a more invasive camer…

This study is testing a new urine test to detect bladder cancer early in people at high risk, such as smokers over 50. Researchers will check how accurate the test is and use the data to build a risk calculator. The goal is to offer a non-invasive way to catch the disease sooner.

This study is testing a new urine test called Bladder CARE™ to see if it can detect bladder cancer in people whose standard tests (cystoscopy or cytology) gave unclear results. About 80 adults with suspicious but inconclusive findings will provide a urine sample before their rout…

This study looks at whether a blood test can detect certain genetic changes (FGFR mutations) in patients with advanced bladder cancer better than the standard tissue biopsy. Currently, only patients with these mutations found in tumor tissue can get the drug erdafitinib. The bloo…

This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see …

This study tests whether new software for ultrasound machines can better detect and measure kidney stones compared to standard methods. Researchers will scan 370 adults with known calcium-based kidney stones and compare the results to CT scans and surgical findings. The goal is t…

This study looks at whether a test that checks for a specific gene marker (SIX6) in urine or tissue can predict if bladder cancer will come back after surgery. Researchers will compare SIX6 levels in 177 patients who had low-risk bladder cancer to see if the test can tell who is …

This study aimed to test a new two-step PET imaging method to better detect cancers that produce a substance called CA19-9, such as pancreatic, bladder, and gastrointestinal tumors. The plan was to give patients an antibody followed by a radioactive tracer to highlight cancer cel…

This study tests whether whole brain radiation can lower the chance of brain tumors in people with small cell carcinoma of the urinary tract (including the bladder). The 31 participants have already had chemotherapy and responded well. They receive radiation to the brain for 3 we…

This phase II trial tests whether a low-dose version of the drug rapamycin, called eRapa, can prevent bladder cancer from coming back in people who have already been treated for non-muscle invasive bladder cancer. About 166 participants will take eRapa or a placebo daily for one …

This Phase 3 trial tests whether a therapeutic BCG vaccine, given directly into the bladder, can prevent non-muscle-invasive bladder cancer from returning after surgery. About 439 adults with intermediate- or high-risk cancer are participating. The study compares BCG to an active…

This Phase 3 trial tests whether Raphamin, an oral tablet, can prevent repeat episodes of chronic bacterial cystitis (a type of urinary tract infection) in women. About 415 women with frequent infections will take either Raphamin or a placebo for six months. The main goal is to s…

This study looks at whether adding high-frequency laser therapy to pelvic floor muscle training helps women with stress urinary incontinence. Thirty-six women will be split into three groups: exercises alone, exercises plus real laser, or exercises plus a fake laser. Researchers …

This study compares two treatments for women with urgency urinary incontinence (sudden, strong urges to urinate that lead to leakage). Participants will be randomly assigned to take an oral beta-agonist pill or receive Botox injections into the bladder. The main goals are to see …

This pilot study tests whether weekly testosterone injections can increase pelvic floor muscle size and improve stress urinary incontinence in women aged 60 and older. The trial involves 30 participants and uses MRI to measure muscle changes. It is a small, early-stage proof-of-c…

This study tests the Revi System, a device that may help people with sudden, strong urges to urinate that cause leaking. About 150 adults who have had this problem for at least 6 months will either get the active device or an inactive version. The goal is to see if the active dev…

This study tests whether a non-invasive magnetic brain stimulation technique, called rTMS, can reduce pain in women with interstitial cystitis or bladder pain syndrome. The treatment targets brain areas that control pelvic floor muscles, aiming to lower pain by improving how the …

This study compares two laser methods for breaking up kidney and ureteral stones during surgery. One method uses standard laser pulses, the other uses a newer 'Moses 2.0' pulse mode. Researchers want to see if the newer mode reduces surgery time and improves stone clearance. Abou…

This study tested a program to help bladder cancer patients recover better after bladder removal surgery. The program included extra monitoring and support before, during, and after the operation to catch problems early. The goal was to reduce complications within 90 days after s…

This study compares two ways of doing pelvic floor muscle training for postmenopausal women with urinary incontinence: one group does the exercises online with a physiotherapist, and the other does them in person. Both groups follow the same exercise plan. The goal is to see if t…

This study looks at whether adding a brief sleep program to standard bladder medication can reduce urgent leaks and nighttime urination in women aged 60 and older. About 120 women with frequent urgency incontinence and nocturia will receive either medication alone or medication p…

This study compares two drugs—methocarbamol and oxybutynin—to see which works better for pain and discomfort caused by a ureteral stent placed after kidney stone surgery. About 126 adults aged 18 to 80 who have the surgery will take one of the study drugs along with standard pain…

This study follows 200 adults with stress or urge incontinence to see how well two surgical procedures work over two years. One surgery tightens ligaments for stress incontinence, the other for urge incontinence. Researchers will measure success by continence rates and track any …

This study tests whether magnetic stimulation of the pelvic floor can help women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). About 158 adult women will receive the treatment and report their symptoms using questionnaires. The goal is t…

This study tests whether a laser applied to the vagina can help women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising). About 144 women will receive the laser treatment and be followed for 6 months. The main goal is to see if the treatment r…

This study looks at whether adding diaphragmatic breathing to standard Kegel exercises can improve pelvic floor muscle strength and quality of life in women who have had multiple pregnancies and suffer from stress urinary incontinence (leaking urine when coughing, sneezing, or ex…

This study tests whether a device that sends mild electrical pulses to a nerve in the ankle (transcutaneous tibial nerve stimulation) can reduce overactive bladder symptoms and improve quality of life in women. Twenty-six women with idiopathic overactive bladder will receive the …

This study is testing whether peppermint oil capsules can improve symptoms of bladder and bowel dysfunction in children aged 8 to 17 who haven't gotten better with standard behavioral therapy. Thirty participants will take peppermint oil three times daily for 8 weeks, and researc…

This Phase 2 trial tests whether a once-daily tablet called ONO-1110 can safely reduce bladder pain in people with Hunner type interstitial cystitis, a painful bladder condition. About 50 Japanese adults will receive either the drug or a placebo for 12 weeks. The main goal is to …

This study looks at two treatments for women with painful bladder syndrome: bladder instillations (medication put directly into the bladder) and pelvic floor physical therapy (exercises to relax tight muscles). The goal is to see which works better to reduce pain and urinary symp…

This study tests a non-invasive treatment called transcutaneous tibial nerve stimulation for women with overactive bladder who cannot or will not take medication. Thirty women will receive either real or sham stimulation twice a week for six weeks. Researchers will measure change…

This study tests whether a 2-minute perineal massage before a pessary exam can reduce pain and discomfort. 68 women with prolapse or incontinence will try both massage and a gel-only method at separate visits. The goal is to find a simple, non-drug way to improve comfort during r…

This study looks at whether reducing the time BCG stays in the bladder (dwell-time) can lessen severe side effects in people with high-risk non-muscle invasive bladder cancer. About 314 patients from Nordic countries will either get the standard dwell-time or a shorter one based …

This study tests whether a wearable device, used at home alongside pelvic floor therapy, can help people with multiple sclerosis manage bladder problems. Twenty women with MS will use the device for three months. The main goal is to see if the approach is practical and easy to us…

This study tests whether a mobile app and a connected device can help women aged 55 and older with stress urinary incontinence do pelvic floor exercises at home. The app guides exercises and provides feedback on muscle contractions. The goal is to see if this approach reduces lea…

This study tests a program of balance and strength exercises, bladder training, and home safety checks in 375 women aged 70 and older who have urinary incontinence. The goal is to see if this approach reduces falls and improves bladder control compared to just giving them informa…

This study looks at two exercise programs for women who leak urine after having a baby. One program uses special breathing and posture exercises (hypopressive exercises), and the other uses standard pelvic floor muscle training. The goal is to see which works better to reduce lea…

This study looks at whether a lower dose of Botox injected into the bladder can effectively treat urgent, frequent bladder leaks in women aged 70 and older. The goal is to reduce symptoms and improve quality of life while possibly causing fewer side effects than the standard dose…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study tests whether a simple behavioral program—like timed bathroom visits and avoiding bladder irritants—works as well as supervised pelvic floor muscle training when both are combined with standard medication for urgency urinary incontinence. Eighty women with this conditi…

This study is testing whether a standardized care plan called Enhanced Recovery After Surgery (ERAS) can help children and young adults recover faster after urologic reconstructive surgery. The plan includes steps before, during, and after surgery to improve pain control and shor…

This study tests a new device called PelviSense that helps women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising) strengthen their pelvic floor muscles using biofeedback. About 132 women aged 18-60 will either use the device with standard ex…

This study tests a two-phase plant-based treatment for women who get frequent bladder infections (at least 4 per year). The treatment uses antibacterial essential oils during an infection and medicinal plants long-term to prevent future episodes. The goal is to see if this approa…

This study looks at whether starting pelvic floor physical therapy before prostate surgery (HoLEP) helps men regain bladder control more quickly after the procedure. About 72 men who are already scheduled for HoLEP to treat an enlarged prostate will be randomly assigned to start …

This study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…

This study planned to see if a 6-week supervised exercise program could reduce symptoms of interstitial cystitis (painful bladder syndrome) and improve quality of life in adult women. Participants would have walked and done light strength training three times a week. However, the…

This study tests whether JING SI HERBAL TEA, a dietary supplement with herbal extracts, can ease lower urinary tract symptoms in bladder cancer patients who have received intravesical therapy. One hundred participants will receive either the herbal tea or a placebo, and their uri…

This study tests whether group physiotherapy is as good as individual sessions for treating urinary incontinence in women aged 60 and older. Over 360 participants will receive either weekly group classes or one-on-one therapy for 12 weeks, both focusing on pelvic floor exercises …

This study aimed to see if giving Botox injections into the bladder at the same time as HoLEP prostate surgery could improve urinary symptoms in men with an enlarged prostate and overactive bladder. The plan was to compare symptom scores and urine flow between men who got both tr…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study is testing a new wireless device called the Glean Urodynamics System (GUS) that monitors bladder pressure without a catheter. It involves 28 adult women with urinary symptoms. Participants will use the device during standard tests and at home. The goal is to see if GUS…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study follows 550 people with bladder cancer to understand how treatments like surgery affect their quality of life. Researchers want to learn what patients go through so doctors can offer better support and clearer information. The goal is to improve care, not to test a new…

This study observes 400 Japanese patients with muscle-invasive urothelial carcinoma who received nivolumab after surgery to remove their cancer. Researchers will track how long patients stay cancer-free, side effects, and how the drug is actually used in clinics. The goal is to s…

This study examines stored tumor samples from 15 people with kidney or bladder cancer who initially responded to immune checkpoint therapy but later developed new tumors. Researchers will compare the genetic and tissue features of the original and new tumors to understand how the…

This study looks at how blood flow to the urethra relates to bladder control. Researchers will use special ultrasound imaging in 70 women—35 with stress urinary incontinence and 35 without—to compare blood supply and pressure measurements. The goal is to better understand what ca…

This early-stage study tests a tiny implantable device that releases very small amounts of several cancer drugs directly into bladder tumors. The goal is to see if the device is safe and can help doctors figure out which drugs kill the tumor best. Only 18 people with muscle-invas…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study looks at how robotic surgery for prostate, bladder, or kidney cancer affects patients' finances. Researchers will ask 120 people who had surgery in the last year to fill out questionnaires about their medical costs, travel expenses, and support needs. The goal is to un…

This study compares two common treatments for recurrent non-muscle-invasive bladder cancer: medical therapy (drugs placed in the bladder) and surgery (bladder removal). Researchers will track quality of life and patient experiences in 570 adults to see which approach works better…

This study is creating a large registry of 600 adults who use catheters to empty their bladder due to nerve damage or other causes. Participants will report on their satisfaction, quality of life, and any infections or complications. The goal is to gather real-world data to bette…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study follows 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. Researchers will collect long-term data on survival, cancer recurrence, and test results to see how well the treatment worked over time. No new…

This study follows 204 people with bladder cancer to see how their quality of life changes after treatment like surgery or radiation. Participants fill out surveys about physical function, pain, fatigue, anxiety, and bladder, bowel, and sexual health. The goal is to understand ho…

This small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…

This study follows 600 people with non-muscle invasive bladder cancer to see how changes in smoking habits and body weight after diagnosis affect the chance of cancer coming back. Participants fill out questionnaires and provide saliva or urine samples over time. The goal is to l…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study aims to find the smallest change in symptom scores that actually matters to patients with overactive bladder. Researchers will treat 104 women with behavioral therapy and nerve stimulation, then analyze questionnaire results. The goal is to help doctors better interpre…

This study tests whether a program that trains primary care doctors can improve how they treat women with urinary incontinence. The program includes lectures, checklists, and tools to help doctors provide better care. Researchers will compare clinics that get the training to thos…

This study looks at how bladder cancer treatments affect people's quality of life years later. Researchers will ask 2000 patients in Denmark about their long-term side effects and what factors might make these worse. The goal is to better understand the real-life impact of treatm…

This study was designed to measure how often urine flows backward from the bladder into the ureter after placing a special stent (RELIEF) in people with kidney stones. Researchers planned to use bladder X-rays to check for reflux and track any symptoms. However, the study was wit…

This study aims to better understand different types of urinary urgency (a sudden, strong need to urinate) in 840 adults. Researchers will look at symptoms, experiences, and other health factors to find patterns. The goal is to lay the groundwork for more personalized and effecti…

This study follows over 1000 men across Europe who had surgery for stress urinary incontinence (leaking urine with coughing, sneezing, or activity). The two surgeries being tracked are the artificial urinary sphincter and the male sling. Researchers will collect data for up to 10…

This study looks at how a person's genes and lifestyle choices, like smoking, affect their risk of getting bladder cancer. Researchers will compare over 6,000 people with and without bladder cancer to find patterns. The goal is to better understand who is most at risk, which coul…

This study looks at why women with stress urinary incontinence (leaking urine when coughing, sneezing, or exercising) develop kinesiophobia—a fear of movement. Researchers will survey 112 women to measure their fear of movement, physical activity levels, incontinence severity, an…

This study analyzes genetic changes in bladder cancer cells from 5,000 participants. Researchers hope to identify key chromosomal events linked to the disease. No treatment is given; the goal is to gather knowledge that may inform future research.

This study tests a guideline designed to help doctors safely reduce or stop overactive bladder medications in people aged 65 and older. Researchers will compare how many patients continue these drugs after six months between those whose doctors follow the guideline and those who …

This study aimed to test whether high-frequency electrical stimulation could improve bladder control in people with spinal cord injury who already have a special device implanted. Researchers planned to compare high-frequency versus low-frequency stimulation in 5 to 10 participan…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) alone or with entinostat affects immune markers in people with muscle-invasive bladder cancer who cannot or choose not to have standard chemotherapy. Twenty participants receive the drugs before the…

This study from the Cleveland Clinic is looking at whether certain migraine medications (CGRP inhibitors) can also improve bladder symptoms like urgency, frequency, and pain. About 200 women with hard-to-treat migraines and bladder issues will be followed for 3 months. Their symp…

This study looks at whether wearable fitness trackers like the Fitbit Sense 2 can help doctors spot early signs of complications in patients recovering from bladder removal surgery. Fifty participants will wear the device and answer daily surveys for up to two weeks before surger…

This study follows 1,600 people with small kidney stones (4 mm or less) to see how often they pass without help. Participants report symptoms, give blood, and get a follow-up CT scan. The goal is to find out if pain, stone size, or location can predict natural passage within 4 to…

This study follows 200 bladder cancer patients who have had their bladder removed (cystectomy) to understand their information needs and how rehabilitation support can be improved. Researchers will track patients over time to see what help they need and how well they cope. The go…

This pilot study tests a new assessment tool called IA3-CP for cancer patients aged 65 and older. The tool gathers information on aging-related issues, mental health, health behaviors, and social factors to help doctors provide better, more personalized care. 35 participants are …

This study creates a large registry of people with and without urothelial cancer (bladder, ureter, or renal pelvis cancer) to learn how genes and lifestyle affect risk. Participants provide a saliva sample and fill out questionnaires. The goal is to improve prevention, diagnosis,…